Emergence and management of drug-resistant enterococcal infections

Area of Science:

• Infectious Diseases
• Clinical Microbiology
• Pharmacology

Background:

• Multidrug-resistant enterococcal infections pose a significant clinical challenge.
• Enterococcus faecium isolates frequently exhibit resistance to glycopeptides, beta-lactams, and other key antibiotics.
• Emerging resistance to newer agents like linezolid and daptomycin further complicates treatment options.

Purpose of the Study:

• To review the current challenges in treating multidrug-resistant enterococcal infections.
• To discuss potential therapeutic options, including newer and older antibiotics.
• To highlight the difficulties in managing endovascular infections caused by these resistant strains.

Main Methods:

• Literature review of antibiotic resistance patterns in enterococci.
• Analysis of available data on new and existing antibiotic agents against resistant strains.
• Evaluation of treatment strategies for endovascular enterococcal infections.

Main Results:

• Many Enterococcus faecium strains are resistant to common antibiotics, including glycopeptides and beta-lactams.
• Newer agents like tigecycline and lipoglycopeptides show potential against specific resistant strains.
• Older antibiotics may retain activity against certain enterococcal isolates.
• Endovascular infections, especially endocarditis, remain difficult to treat effectively.

Conclusions:

• Effective treatment of multidrug-resistant enterococcal infections requires careful consideration of species identification and susceptibility testing.
• Optimal therapeutic regimens for endovascular infections are not well-established and often rely on limited data.
• A personalized, case-by-case approach, informed by clinical and microbiological data, is crucial for selecting active therapeutic strategies.